Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials
Claire Gallois(Université Paris Cité), Demetris Papamichael(Bank of Cyprus Oncology Center), Steven R. Alberts(North Central Cancer Treatment Group), Thomas J. George(University of Florida Health), Julien Taı̈eb(Hôpital Européen Georges-Pompidou), Jeffrey A. Meyerhardt(CancerCare), Andrea Harkin(Queen's University Belfast), Qian Shi(Mayo Clinic), Sara Lonardi(Istituto Oncologico Veneto), Levi Pederson(Mayo Clinic in Florida), Aimery de Gramont(Institut Hospitalier Franco Britannique), Timothy Iveson(University Hospital Southampton NHS Foundation Trust), Greg Yothers(University of Pittsburgh), Takayuki Yoshino(University of Tsukuba), Eiji Oki(Kyushu University), Frank A. Sinicrope(Mayo Clinic in Arizona), Anthony F. Shields(Wayne State University), Thierry André(Inserm), Ioannis Souglakos(University of Crete), Richard M. Goldberg(Ontario Institute for Cancer Research), Roberto Labianca(Ospedale Papa Giovanni XXIII), Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), Rachel Kerr(Cancer Research UK Clinical Trials Unit), Alberto F. Sobrero(Ospedale Policlinico San Martino), Ioannis Boukovinas
Cited by 25
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
|New England Journal of Medicine|2020|2.9k